Free tool
FAERS Monitor: Xalatan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020597 or its brand name (Xalatan, Latanoprost). Reports on generic versions are filed under their own applications.
Reports
50,175
Serious
27,826
55% of reports
Hospitalization
10,574
Death reported
3,136
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure5,934
- drug ineffective3,267
- fatigue2,378
- eye irritation2,178
- headache1,837
- intraocular pressure increased1,787
- dyspnoea1,678
- diarrhoea1,676
- dizziness1,655
- off label use1,647
- eye pain1,642
- death1,620
- nausea1,597
- vision blurred1,520
- fall1,460
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 427 |
| 2005 | 616 |
| 2006 | 656 |
| 2007 | 703 |
| 2008 | 719 |
| 2009 | 834 |
| 2010 | 2,052 |
| 2011 | 1,687 |
| 2012 | 1,971 |
| 2013 | 1,643 |
| 2014 | 1,876 |
| 2015 | 2,271 |
| 2016 | 2,722 |
| 2017 | 2,570 |
| 2018 | 2,846 |
| 2019 | 3,051 |
| 2020 | 8,873 |
| 2021 | 2,408 |
| 2022 | 2,369 |
| 2023 | 2,431 |
| 2024 | 2,481 |
| 2025 | 2,766 |
| 2026 | 2,203 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,003,984 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 1,787 | 68.0 | 64.7 | 101,446 |
| treatment failureSignal | 5,934 | 32.3 | 31.5 | 167,532 |
| eye irritationSignal | 2,178 | 16.4 | 15.8 | 30,470 |
| eye painSignal | 1,642 | 12.5 | 11.9 | 16,957 |
| vision blurredSignal | 1,520 | 4.7 | 4.5 | 4,376 |
| fall | 1,460 | 1.8 | 1.8 | 568 |
| dizziness | 1,655 | 1.4 | 1.3 | 186 |
| fatigue | 2,378 | 1.3 | 1.2 | 152 |
| dyspnoea | 1,678 | 1.2 | 1.2 | 82 |
| headache | 1,837 | 1.2 | 1.2 | 80 |
| diarrhoea | 1,676 | 1.1 | 1.0 | 12 |
| drug ineffective | 3,267 | 1.0 | 1.0 | 5 |
| nausea | 1,597 | 0.8 | 0.8 | 47 |
| off label use | 1,647 | 0.8 | 0.8 | 98 |
| death | 1,620 | 0.8 | 0.8 | 96 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.